SciELO - Scientific Electronic Library Online

 
vol.34 número3Kidney disease in tuberous sclerosis complex: A single-center experienceAcute kidney injury in SARS-COV-2 infection índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Portuguese Journal of Nephrology & Hypertension

versão impressa ISSN 0872-0169

Resumo

MENEZES, Maria do Mar; AIRES, Inês  e  NOLASCO, Fernando. Antibody mediated rejection. Evidence based medicine. What is the current evidence?. Port J Nephrol Hypert [online]. 2020, vol.34, n.3, pp.150-156. ISSN 0872-0169.  https://doi.org/10.32932/pjnh.2020.10.085.

Antibody mediated rejection (ABMR) is a major cause of kidney graft loss. The ideal treatment remains unknown, is not standardized and there is little evidence to support the use of any specific therapy. This paper aims to reflect on the current state of this challenging diagnosis, either active or chronic active ABMR, and its treatment options. The current treatments encompass plasma exchange, steroids, intravenous immunoglobulin, rituximab, bortezomib, eculizumab, C1 inhibitors, IL 6 inhibitors and IgG-degrading enzyme of Streptococcus pyogenes among others. We will try to analyze the main studies that sustain or reject the current and future use of these techniques and drugs.

Palavras-chave : Antibody mediated rejection; donor-specific antibodies; kidney transplant; microvascular injury; renal allograft failure.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons